<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106219</url>
  </required_header>
  <id_info>
    <org_study_id>17295</org_study_id>
    <secondary_id>J1O-MC-JZHD</secondary_id>
    <secondary_id>2019-001042-18</secondary_id>
    <secondary_id>2019-01</secondary_id>
    <secondary_id>ITCC-085</secondary_id>
    <nct_id>NCT04106219</nct_id>
  </id_info>
  <brief_title>A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma</brief_title>
  <official_title>A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Approaches to Neuroblastoma Therapy Consortium (NANT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Therapies for Children with Cancer in Europe (ITCC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug LY3295668 erbumine is safe in
      participants with relapsed/refractory neuroblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">April 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 2 (28 Day Cycle)</time_frame>
    <description>Number of Participants with DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 5 Years)</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 5 Years)</time_frame>
    <description>DoR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3295668</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3295668 in Combination with Topotecan and Cyclophosphamide</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3295668 in Combination with topotecan and cyclophosphamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR): Percentage of Participants with CR, PR, Stable Disease (SD), or Progressive Disease (PD)</measure>
    <time_frame>Baseline to Date of Objective Disease Progression (Estimated up to 5 Years)</time_frame>
    <description>BOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 5 Years)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Estimated up to 6 Years)</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 Erbumine given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 Erbumine given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3295668 Erbumine</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion</arm_group_label>
    <arm_group_label>LY3295668 Erbumine Escalation</arm_group_label>
    <arm_group_label>LY3295668 Erbumine Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have relapsed/refractory neuroblastoma and have active disease in at
             least one site: bone, bone marrow or soft tissue. Participants must be able to submit
             an archival sample of tissue.

          -  Participants must be able to swallow capsules.

        Exclusion Criteria:

          -  Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or
             solid organ transplant.

          -  Participants must not have untreated tumor that has spread to the brain or spinal
             cord.

          -  Participants must not have a serious active disease other than neuroblastoma.

          -  Participants must not have a condition affecting absorption.

          -  Participants must not have had prior aurora kinase inhibitor exposure.

          -  Participants must not have a known allergy to the study treatment.

          -  Participants must not have symptomatic human immunodeficiency virus (HIV) infection or
             symptomatic activated/reactivated hepatitis A, B, or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-669-2101</phone>
    </contact>
    <investigator>
      <last_name>Araz Marachelian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Approaches to Neuroblastoma Therapy (NANT)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-361-5687</phone>
    </contact>
    <investigator>
      <last_name>NANT Network</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kieuhoa Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>7207776740</phone>
    </contact>
    <investigator>
      <last_name>Margaret Ellen Macy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Heathcare of Atlanta, Inc. at Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kelly C Goldsmith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago - Comer Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ami V Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-5869</phone>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-639-5204</phone>
    </contact>
    <investigator>
      <last_name>Ellen Basu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine - Children's Hospital - Children's Research Institute</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-962-4991</phone>
    </contact>
    <investigator>
      <last_name>Patrick A. Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-381-9900</phone>
    </contact>
    <investigator>
      <last_name>Chad Jacobsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>513-636-9863</phone>
    </contact>
    <investigator>
      <last_name>Brian Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-590-0965</phone>
    </contact>
    <investigator>
      <last_name>Yael Mosse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Childrens Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-595-5007</phone>
    </contact>
    <investigator>
      <last_name>Michael W Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>682-885-4007</phone>
    </contact>
    <investigator>
      <last_name>Meaghan Granger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>832-824-4632</phone>
    </contact>
    <investigator>
      <last_name>Jodi Muscal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-987-2114</phone>
    </contact>
    <investigator>
      <last_name>Navin R Pinto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sydney Children's Hospitals Network</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61413256876</phone>
    </contact>
    <investigator>
      <last_name>Bhavna Padhye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Childrens Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61393454592</phone>
    </contact>
    <investigator>
      <last_name>Martin Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61864563612</phone>
    </contact>
    <investigator>
      <last_name>Nicholas Gottardo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3293324812</phone>
    </contact>
    <investigator>
      <last_name>Bram De Wilde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4168137654</phone>
    </contact>
    <investigator>
      <last_name>Daniel Morgenstern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33469166572</phone>
    </contact>
    <investigator>
      <last_name>Nadege Corradini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris CEDEX 05</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33 1 44 32 46 01</phone>
    </contact>
    <investigator>
      <last_name>Isabelle Aerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33 5 34 55 86 11</phone>
    </contact>
    <investigator>
      <last_name>Marion Gambart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4930450566132</phone>
    </contact>
    <investigator>
      <last_name>Angelika Eggert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>492214786854</phone>
    </contact>
    <investigator>
      <last_name>Matthias Fischer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini Ospedale Pediatrico I.R.C.C.S.</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>01056363582</phone>
    </contact>
    <investigator>
      <last_name>Loredana Amoroso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Lombardie</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>390223902592</phone>
    </contact>
    <investigator>
      <last_name>Roberto Luksch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Margherita di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390113131865</phone>
    </contact>
    <investigator>
      <last_name>Nicoletta Bertorello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Chitose Ogawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34 93 489 30 00 ext 3093</phone>
    </contact>
    <investigator>
      <last_name>Lucas Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0034 915 03 59 00 - Extensión</phone>
    </contact>
    <investigator>
      <last_name>Francisco José Bautista Sirvent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34686933743</phone>
    </contact>
    <investigator>
      <last_name>Adela Cañete Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>01223256298</phone>
    </contact>
    <investigator>
      <last_name>Amos Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>Bloomsbury</city>
        <state>London</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>02074059200 ext. 5379</phone>
    </contact>
    <investigator>
      <last_name>Giuseppe Barone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0113 3928779</phone>
    </contact>
    <investigator>
      <last_name>Martin Elliott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>01512933679</phone>
    </contact>
    <investigator>
      <last_name>Lisa Howell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/neuroblastoma/JZHD#?postal=</url>
    <description>A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma</description>
  </link>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aurora kinase A</keyword>
  <keyword>kinase</keyword>
  <keyword>aurora A</keyword>
  <keyword>aurora kinase inhibitor</keyword>
  <keyword>aurora kinase A inhibitor</keyword>
  <keyword>kinase inhibitor</keyword>
  <keyword>AURKA</keyword>
  <keyword>AurA</keyword>
  <keyword>pediatric neuroblastoma</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

